| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/21/1999 | CN1223651A Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors |
| 07/21/1999 | CN1223579A Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
| 07/21/1999 | CN1044245C Tricyclic dicarbonyl derivatives, medicinal compositions and use thereof |
| 07/20/1999 | US5925684 Stable oil in water emulsion containing carotenoid, ethylene oxide-propylene oxide block copolymer emulsifier |
| 07/20/1999 | US5925668 Thioctic metabolites and methods of use thereof |
| 07/20/1999 | US5925665 Imidazoline compounds |
| 07/20/1999 | US5925646 Heterocyclic aryl-, alkyl- and cycloalkylacetamides |
| 07/20/1999 | US5925645 Arteriosclerosis |
| 07/20/1999 | US5925539 Human pelota homolog |
| 07/20/1999 | US5925521 Human serine carboxypeptidase |
| 07/20/1999 | US5925382 Antioxidant composition and method for production thereof |
| 07/20/1999 | US5925351 Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| 07/20/1999 | US5925333 Screening for compounds that alter the binding by scavengers |
| 07/20/1999 | CA2024419C Novel bivalent metal salts of n,n-di(carboxymethyl)-2-amino-3-cyano-4-carboxymethyl-5-carboxythiophene acid, process for their preparation and pharmaceutical compositions containing them |
| 07/15/1999 | WO1999035163A1 Phenylalanine derivatives |
| 07/15/1999 | WO1999035147A1 Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes |
| 07/15/1999 | WO1999035135A1 Hypolipidemic benzothiazepine compounds |
| 07/15/1999 | WO1999035131A1 Aryl fused azapolycyclic compounds |
| 07/15/1999 | WO1999034834A1 Use of pigmented retinal epithelial cells for creation of an immune privilege site |
| 07/15/1999 | WO1999034822A1 Formulations for amylin agonist peptides |
| 07/15/1999 | WO1999034821A1 Stabilised insulin compositions |
| 07/15/1999 | WO1999034816A1 Method for administering monomeric insulin analogs |
| 07/15/1999 | WO1999034815A1 Method for administering aspb28-human insulin |
| 07/15/1999 | WO1999034787A2 Fat-binding polymers |
| 07/15/1999 | WO1999034786A2 Lipase inhibiting polymers |
| 07/15/1999 | CA2365742A1 Formulations for amylin agonist peptides |
| 07/15/1999 | CA2318417A1 Fat-binding polymers |
| 07/15/1999 | CA2318416A1 Polymers comprising lipase inhibiting groups |
| 07/15/1999 | CA2317739A1 Method for administering aspb28-human insulin |
| 07/15/1999 | CA2317733A1 Method for administering monomeric insulin analogs |
| 07/15/1999 | CA2317651A1 Hypolipidemic benzothiazepine compounds |
| 07/15/1999 | CA2315736A1 Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
| 07/14/1999 | EP0928197A1 Use of proteins as agents against autoimmune diseases |
| 07/14/1999 | EP0928196A1 Beta-glucan products and extraction processes from cereals |
| 07/14/1999 | EP0928194A1 Compositions and methods for administering integrin receptor antagonists |
| 07/14/1999 | EP0754234B1 DNA ENCODING PRECURSOR OF INTERLEUKIN-1 BETA CONVERTING ENZYME-RELATED CYSTEINE PROTEINASE II (ICE rel-II) |
| 07/14/1999 | EP0658161B1 Substituted thiazolidinedione derivatives |
| 07/14/1999 | EP0619729B1 Composition to help stop smoking |
| 07/14/1999 | EP0581856B1 Method of preventing nmda receptor complex-mediated neuronal damage |
| 07/14/1999 | CN1222917A Novel protein and process for producing the same |
| 07/14/1999 | CN1222905A New synthetic catechol derivatives, method for production and use thereof |
| 07/14/1999 | CN1222521A 1,3,8-triaza-spiro [4,5] decan-4-on derivatives |
| 07/14/1999 | CN1222349A Brain nourishing composition |
| 07/14/1999 | CN1044116C Novel benzenesulfonylimine derivatives as inhibitors of IL-1 action and use thereof |
| 07/13/1999 | US5922853 Human pelota homolog |
| 07/13/1999 | US5922773 Treatment with n-methyl-d-aspartate antagonist for vision defects |
| 07/13/1999 | US5922766 Palatable elemental medical food |
| 07/13/1999 | US5922761 Methods for in vivo reduction of iron levels and compositions useful therefor |
| 07/13/1999 | US5922740 Antiinflammatory agents |
| 07/13/1999 | US5922718 Triazolones as apolipoprotein-B synthesis inhibitors |
| 07/13/1999 | US5922716 Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (ampa) receptor antagonists, non-competitive n-methyl-d-aspartate (nmda) receptor antagonists |
| 07/13/1999 | US5922675 A mixture of fatty acid amidated polypeptides and regular insulin for treating diabetes, use an extended duration of action |
| 07/13/1999 | US5922571 Polynucleotides encoding a protein kinase C homolog |
| 07/13/1999 | CA2162249C Cholesterol lowering drink mix compositions |
| 07/08/1999 | WO1999033873A1 NOVEL POLYPEPTIDES, cDNAS ENCODING THE SAME AND UTILIZATION THEREOF |
| 07/08/1999 | WO1999033859A2 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| 07/08/1999 | WO1999033825A1 N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them |
| 07/08/1999 | WO1999033822A1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 07/08/1999 | WO1999033821A1 Benzopyran and benzothiopyran derivatives having retinoid antagonist-like activity |
| 07/08/1999 | WO1999033801A1 Tripeptidyl peptidase inhibitors |
| 07/08/1999 | WO1999033479A1 Use of parasitic biological agents for prevention and control of autoimmune diseases |
| 07/08/1999 | WO1999033475A1 Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications |
| 07/08/1999 | WO1999033474A1 The use of mannose for combating protein loss enteropathy |
| 07/08/1999 | WO1999033466A1 Pharmaceutical composition for oral administration |
| 07/08/1999 | WO1999033460A1 Acyl guanidine sodium/proton exchange inhibitors and method |
| 07/08/1999 | WO1999033450A2 Pharmaceutical composition containing sibutramine and orlistat |
| 07/08/1999 | WO1999033355A2 Fat blend |
| 07/08/1999 | WO1999020739A3 Novel lactic acid bacteria species |
| 07/08/1999 | WO1999011606A3 Inhibitors of protein tyrosine phosphatase |
| 07/08/1999 | DE19758059A1 Verwendung von Mannose zur Bekämpfung der Proteinverlust-Enteropathie Use of mannose to combat protein-losing enteropathy |
| 07/08/1999 | CA2316382A1 N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them |
| 07/08/1999 | CA2316352A1 Acyl guanidine sodium/proton exchange inhibitors and method |
| 07/08/1999 | CA2316041A1 Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications |
| 07/08/1999 | CA2315790A1 Use of parasitic biological agents for prevention and control of autoimmune diseases |
| 07/08/1999 | CA2315723A1 Indole derivatives useful a.o. for the treatment of osteoporosis |
| 07/08/1999 | CA2315259A1 Pharmaceutical composition containing sibutramine and orlistat |
| 07/07/1999 | EP0927555A1 Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia |
| 07/07/1999 | EP0927192A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| 07/07/1999 | EP0927183A1 Spirocyclic metalloprotease inhibitors |
| 07/07/1999 | EP0927166A1 Amides as npy5 receptor antagonists |
| 07/07/1999 | EP0927161A1 Substituted cyclic amine metalloprotease inhibitors |
| 07/07/1999 | EP0927046A1 Mammalian regulator of nonsense-mediated rna decay |
| 07/07/1999 | EP0927041A2 Treatment of diabetes |
| 07/07/1999 | EP0927039A1 Induction of a cellular stress response with heavy metal salts |
| 07/07/1999 | EP0927028A1 Use of sibutramine analogues to prevent the development of diabetes |
| 07/07/1999 | EP0636027B1 Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| 07/07/1999 | EP0502188B1 Cloned glutamic acid decarboxylase |
| 07/07/1999 | CN1221620A Compound medicine for treating diabets mellitus |
| 07/06/1999 | US5919943 Inhibition of spla2 |
| 07/06/1999 | US5919829 Gastrin and cck receptor ligands |
| 07/06/1999 | US5919818 Tocotrienols and tocotrienol-like compounds and methods for their use |
| 07/06/1999 | US5919814 Heterocyclic compounds |
| 07/06/1999 | US5919810 1H-indole-3-glyoxylamide sPLA2 inhibitors |
| 07/06/1999 | US5919809 3-substituted-2-oxindole derivatives |
| 07/06/1999 | US5919807 Benzothiazoles and benzoxazoles, drugs containing them, their use and methods of preparing them |
| 07/06/1999 | US5919795 Atherosclerosis therapy |
| 07/06/1999 | US5919793 Quinuclidine derivatives, squalene synthetase inhibitors, anticholesterol agents |
| 07/06/1999 | US5919789 Xanthines and their therapeutic use |
| 07/06/1999 | US5919692 Ubiquitous ATP-sensitive potassium-channel genes |
| 07/06/1999 | US5919687 Polynucleotide coding for neutral sphingomyelinase; for screening compounds for diagnosis and treatment of diseases; antiarthritic/antitumor/anticarcinogenic/anticholesterol agents; psychological/nervous system disorders |